Hyperglycemia and Diabetes Mellitus Following Organ Transplantation

Rodolfo J. Galindo*, Amisha Wallia

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations


Hyperglycemia is common following organ transplantation, regardless of the pre-transplant diabetes status. Transient post-transplant hyperglycemia and/or new-onset diabetes after transplantation (NODAT) are common and are associated with increased morbidity and mortality. NODAT and type 2 diabetes share similar characteristics, but the pathophysiology may differ. Immunosuppressive agents and steroids play a key role in the development of NODAT. Glycemic control is challenging in this population due to fluctuating renal/end-organ function, immunosuppressive dosing, nutritional status, and drug-drug interactions. A proactive and multidisciplinary approach is essential, along with flexible protocols to adjust to patient status, type of organ transplanted, and corticosteroid regimens. Insulin is the preferred agent for hospitalized patients and during the early post-transplant period; optimal glycemic control (BG < 180 mg/dl with minimal hypoglycemia [<70 mg/dl]) is desired.

Original languageEnglish (US)
Article number14
Pages (from-to)1-11
Number of pages11
JournalCurrent diabetes reports
Issue number2
StatePublished - Feb 1 2016


  • Diabetes mellitus
  • Hyperglycemia
  • New-onset diabetes after transplantation
  • Organ transplantation
  • Outcomes
  • Post-transplant diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Hyperglycemia and Diabetes Mellitus Following Organ Transplantation'. Together they form a unique fingerprint.

Cite this